Efficacy of Combined Therapy With Silodosin and Solifenacin in Females With Overactive Bladder
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: We aimed to assess the clinical efficacy and safety of combining silodosin and solifenacin for overactive bladder (OAB) in females. Methods: A retrospective analysis of 586 females with OAB was conducted. Patients received either combination therapy (silodosin 8 mg + solifenacin 5 mg) or monotherapy (solifenacin 5 mg) for 12 weeks. Baseline and follow-up assessments included the overactive bladder symptom score (OABSS), International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), voided volume (VV), and postvoid residual urine volume (PVR). Results: Overall, 287 and 299 patients received combination therapy and monotherapy respectively. Both groups experienced significant improvements in OABSS and total IPSS after 12 weeks. The combination therapy group demonstrated a greater improvement in QoL compared to the monotherapy group (P=0.031). No significant differences were observed in Qmax or VV between the groups. However, the combination therapy group showed a significant reduction in PVR compared to the monotherapy group (P<0.001). Conclusions: Combining silodosin with solifenacin significantly improved OAB symptoms and QoL in females. This combination therapy was particularly effective in reducing postvoid residual volume compared to solifenacin alone. These findings suggest that adding an alpha-blocker to antimuscarinic therapy can enhance OAB management and patient satisfaction.
Abstract
Purpose: We aimed to assess the clinical efficacy and safety of combining silodosin and solifenacin for overactive bladder (OAB) in females. Methods: A retrospective analysis of 586 females with OAB was conducted. Patients received either combination therapy (silodosin 8 mg + solifenacin 5 mg) or monotherapy (solifenacin 5 mg) for 12 weeks. Baseline and follow-up assessments included the overactive bladder symptom score (OABSS), International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), voided volume (VV), and postvoid residual urine volume (PVR). Results: Overall, 287 and 299 patients received combination therapy and monotherapy respectively. Both groups experienced significant improvements in OABSS and total IPSS after 12 weeks. The combination therapy group demonstrated a greater improvement in QoL compared to the monotherapy group (P=0.031). No significant differences were observed in Qmax or VV between the groups. However, the combination therapy group showed a significant reduction in PVR compared to the monotherapy group (P<0.001). Conclusions: Combining silodosin with solifenacin significantly improved OAB symptoms and QoL in females. This combination therapy was particularly effective in reducing postvoid residual volume compared to solifenacin alone. These findings suggest that adding an alpha-blocker to antimuscarinic therapy can enhance OAB management and patient satisfaction.
참고문헌 (18)
- Haylen BT, "An International Urogynecological Association(IUGA)", International Continence Society(ICS)joint report on the terminology for female pelvic floor dysfunction, 2010, pp.29, 4~20
- Lee YS, "Prevalence of overactive bladder, urinary incontinence, and lower urinary tract symptoms : results of Korean EPIC study", World J Urol, 29, pp.185~190 (2011)
- Chapple CR, "Solifenacin significantly improves all symptoms of overactive bladder syndrome", Int J Clin Pract, 60, pp.959~966 (2006)
- Xu Y, "Meta-analysis of the efficacy and safety of mirabegron add-on therapy to solifenacin for overactive bladder", Int Neurourol J, 21, pp.212~219 (2017)
- Raj MO, "Therapeutic effectiveness and adverse drug reactions of mirabegron versus solifenacin in the treatment of overactive bladder syndrome", Perspect Clin Res, 15, pp.147~151 (2024)
- Stanton SL, "Voiding difficulties in the female : prevalence, clinical and urodynamic review", Obstet Gynecol, 61, pp.144~147 (1983)
- Moon KH, "A 12-week, open label, multi-center study to evaluate the clinical efficacy and safety of silodosin on voiding dysfunction in patients with neurogenic bladder", Low Urin Tract Symptoms, 7, pp.27~31 (2015)
- Yamanishi T, "Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia", Neurourol Urodyn, 29, pp.558~562 (2010)
- Kang TW, "Effect of symptom-based alpha-blocker treatment on lower urinary tract symptoms in women : systematic review and meta-analysis", Ther Adv Urol, 13, pp.17562872211053679~ (2021)
- Lee SH, "Initial combined treatment with anticholinergics and α-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder : a prospective, randomized, multi-center, double-blind, placebo-controlled study", Prostate Cancer Prostatic Dis, 14, pp.320~325 (2011)
- Kim HJ, "Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms : updated meta-analysis", PLoS One, 12, pp.e0169248~ (2017)
- Hao N, "Antimuscarinics and α-blockers or α-blockers monotherapy on lower urinary tract symptoms–a meta-analysis", Urology, 83, pp.556~562 (2014)
- Pang R, "Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction", Cochrane Database Syst Rev, 2, pp.CD012336~ (2021)
- Kim SO, "Efficacy and safety of combined therapy with tamsulosin and tolterodine in female patients with a maximal flow rate less than 12 ml", s, 2011, pp.22, 1287~1291
- Meyer LE, "Tamsulosin for voiding dysfunction in women", Int Urol Nephrol, 44, pp.1649~1656 (2012)
- Boyd K, "α-adrenergic blockers for the treatment of lowerurinary-tract symptoms and dysfunction in women", Ann Pharmacother, 48, pp.711~722 (2014)
- Hiremath S, "Alpha-blocker use and the risk of hypotension and hypotension-related clinical events in women of advanced age", Hypertension, 74, pp.645~651 (2019)
- Lee YS, "Efficacy of an alpha-blocker for the treatment of nonneurogenic voiding dysfunction in women : an 8-week, randomized, double-blind, placebo-controlled trial", Int Neurourol J, 22, pp.30~40 (2018)